The novel new vaccine, which involves injecting weakened malarial-inducing parasites into patients in order to elicit a degree of immunity, has been having successful results. The U.S. biotech company, Sanaria, hopes for continued success in order to alleviate the impact of the widespread disease.
NOT FOR REPRINT
Malaria vaccine shows early promise in clinical trials
By
staff Writer
August 11, 2013 at 02:36 PM
Share & Print
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
